Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) PT at $16.75

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned an average recommendation of “Hold” from the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $16.75.

Several analysts have recently commented on ELAN shares. Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Leerink Partners initiated coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Barclays upped their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, UBS Group initiated coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective on the stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of ELAN. Benjamin F. Edwards & Company Inc. grew its position in shares of Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares during the period. ORG Wealth Partners LLC bought a new position in Elanco Animal Health during the third quarter valued at $29,000. nVerses Capital LLC bought a new position in Elanco Animal Health during the second quarter valued at $32,000. AM Squared Ltd bought a new stake in shares of Elanco Animal Health in the third quarter valued at $34,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the third quarter valued at $35,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 4.7 %

Shares of NYSE:ELAN opened at $11.73 on Monday. Elanco Animal Health has a 1 year low of $11.40 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The business’s 50-day moving average is $13.07 and its 200-day moving average is $14.21. The company has a market capitalization of $5.80 billion, a price-to-earnings ratio of 29.33, a P/E/G ratio of 2.03 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.18 EPS. Equities research analysts predict that Elanco Animal Health will post 0.92 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.